RU2606853C2 - Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания - Google Patents

Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания Download PDF

Info

Publication number
RU2606853C2
RU2606853C2 RU2012142181A RU2012142181A RU2606853C2 RU 2606853 C2 RU2606853 C2 RU 2606853C2 RU 2012142181 A RU2012142181 A RU 2012142181A RU 2012142181 A RU2012142181 A RU 2012142181A RU 2606853 C2 RU2606853 C2 RU 2606853C2
Authority
RU
Russia
Prior art keywords
ethyl
approximately
epa
initial
patient
Prior art date
Application number
RU2012142181A
Other languages
English (en)
Russian (ru)
Other versions
RU2012142181A (ru
Inventor
Джонатан РОУ
Original Assignee
Амарин Фармасьютикалз Айрлэнд Лимитед (Апил)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) filed Critical Амарин Фармасьютикалз Айрлэнд Лимитед (Апил)
Publication of RU2012142181A publication Critical patent/RU2012142181A/ru
Application granted granted Critical
Publication of RU2606853C2 publication Critical patent/RU2606853C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2012142181A 2010-03-04 2011-03-04 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания RU2606853C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31044310P 2010-03-04 2010-03-04
US61/310,443 2010-03-04
PCT/US2011/027218 WO2011109724A1 (en) 2010-03-04 2011-03-04 Compositions and methods for treating and/or preventing cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016129266A Division RU2728825C2 (ru) 2010-03-04 2011-03-04 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания

Publications (2)

Publication Number Publication Date
RU2012142181A RU2012142181A (ru) 2014-04-10
RU2606853C2 true RU2606853C2 (ru) 2017-01-10

Family

ID=44531868

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2012142181A RU2606853C2 (ru) 2010-03-04 2011-03-04 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
RU2016129266A RU2728825C2 (ru) 2010-03-04 2011-03-04 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
RU2020123679A RU2020123679A (ru) 2010-03-04 2020-07-17 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2016129266A RU2728825C2 (ru) 2010-03-04 2011-03-04 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
RU2020123679A RU2020123679A (ru) 2010-03-04 2020-07-17 Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания

Country Status (13)

Country Link
US (10) US20110218243A1 (cg-RX-API-DMAC7.html)
EP (2) EP3583849A1 (cg-RX-API-DMAC7.html)
JP (5) JP6327497B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130026428A (cg-RX-API-DMAC7.html)
AU (1) AU2011222544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012022336A2 (cg-RX-API-DMAC7.html)
CA (4) CA3066588C (cg-RX-API-DMAC7.html)
ES (1) ES2750365T3 (cg-RX-API-DMAC7.html)
MX (1) MX337315B (cg-RX-API-DMAC7.html)
PH (3) PH12012501755A1 (cg-RX-API-DMAC7.html)
RU (3) RU2606853C2 (cg-RX-API-DMAC7.html)
SG (1) SG183883A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011109724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009288066B2 (en) 2008-09-02 2015-12-24 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
CA3129996C (en) 2009-06-15 2025-09-02 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
BR112012022336A2 (pt) * 2010-03-04 2020-07-21 Amarin Pharma, Inc. composições e seus usos para tratar e/ou prevenir doença cardiovascular
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) * 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
CA2878267A1 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of treating pediatric metabolic syndrome
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
WO2014063190A1 (en) * 2012-10-23 2014-05-01 Deakin University Method for reducing triglycerides
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221676A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) * 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
DK4056176T3 (da) 2018-09-24 2024-05-06 Amarin Pharmaceuticals Ie Ltd Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
WO2021097120A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
KR20240012390A (ko) * 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
CN113346980B (zh) * 2021-08-02 2023-08-11 浙江国利信安科技有限公司 用于消息转发的方法、电子设备和计算机存储介质

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA1338683C (en) * 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) * 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
US5215630A (en) * 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) * 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JPH0959206A (ja) * 1995-08-25 1997-03-04 Nippon Oil & Fats Co Ltd エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
AU731692C (en) * 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US6531150B1 (en) * 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
ATE394941T1 (de) * 1999-07-28 2008-05-15 Swiss Caps Rechte & Lizenzen Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung
EP1211955A1 (en) * 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
JP4170542B2 (ja) * 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
DE60203494T2 (de) * 2001-05-30 2006-02-09 Laxdale Ltd. Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
US7314643B2 (en) * 2002-08-20 2008-01-01 Nikken Chemicals Co., Ltd. Soft capsule preparation
KR20110053281A (ko) * 2002-11-22 2011-05-19 니폰스이산가부시키가이샤 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는 조성물
EP1711173A2 (en) * 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2006085144A2 (en) * 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions containing high omega-3 and low saturated fatty acid levels
EP1830830A4 (en) * 2004-12-06 2010-02-10 Reliant Pharmaceuticals Inc OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC MEANS FOR LIPID THERAPY
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
ES2511772T3 (es) * 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
US7498359B2 (en) * 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
EP2022495B1 (en) * 2006-05-31 2014-07-23 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
AU2007270135B9 (en) * 2006-07-05 2013-06-27 Fermentalg Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) * 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
PT3037089T (pt) * 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia
CA3129996C (en) * 2009-06-15 2025-09-02 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY
BR112012022336A2 (pt) * 2010-03-04 2020-07-21 Amarin Pharma, Inc. composições e seus usos para tratar e/ou prevenir doença cardiovascular

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIAL NCT01047501. Effect of AMP101 (ethyl icosapentate) on triglyceride (Tg) levels in patients on statin with high Tg levels (! 200 and *

Also Published As

Publication number Publication date
BR112012022336A2 (pt) 2020-07-21
RU2020123679A (ru) 2022-01-17
WO2011109724A1 (en) 2011-09-09
US20150335607A1 (en) 2015-11-26
PH12018500843B1 (en) 2022-02-18
RU2728825C2 (ru) 2020-07-31
US20110218243A1 (en) 2011-09-08
AU2011222544A1 (en) 2012-09-27
ES2750365T3 (es) 2020-03-25
CA2792090C (en) 2019-05-14
JP2020183428A (ja) 2020-11-12
CA3043081A1 (en) 2011-09-09
US20140128464A1 (en) 2014-05-08
JP2017025089A (ja) 2017-02-02
US20220323393A1 (en) 2022-10-13
US20200360330A1 (en) 2020-11-19
EP3583849A1 (en) 2019-12-25
JP2020128412A (ja) 2020-08-27
EP2542060A1 (en) 2013-01-09
EP2542060A4 (en) 2013-08-14
JP2019048843A (ja) 2019-03-28
EP2542060B1 (en) 2019-10-02
RU2012142181A (ru) 2014-04-10
PH12018500843A1 (en) 2019-02-27
JP7136526B2 (ja) 2022-09-13
CA3043081C (en) 2020-02-11
JP6327497B2 (ja) 2018-05-23
US20240216322A1 (en) 2024-07-04
PH12021550756A1 (en) 2022-02-21
RU2020123679A3 (cg-RX-API-DMAC7.html) 2022-01-26
US20210386701A1 (en) 2021-12-16
MX2012010253A (es) 2012-12-17
CA3147657A1 (en) 2011-09-09
CA3147657C (en) 2023-03-07
US20210260016A1 (en) 2021-08-26
MX337315B (es) 2016-02-25
CA3066588C (en) 2022-03-22
JP2013521310A (ja) 2013-06-10
PH12012501755A1 (en) 2012-11-12
KR20130026428A (ko) 2013-03-13
US20170128406A1 (en) 2017-05-11
RU2016129266A3 (cg-RX-API-DMAC7.html) 2019-12-27
CA3066588A1 (en) 2011-09-09
CA2792090A1 (en) 2011-09-09
US20200297681A1 (en) 2020-09-24
RU2016129266A (ru) 2018-12-07
SG183883A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
RU2606853C2 (ru) Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
US11712428B2 (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
RU2519043C2 (ru) Композиции и способы понижения уровня триглицеридов без повышения уровня хс-лпнп у субъекта, получающего сопутствующую терапию
US11712429B2 (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
HK40018897A (en) Compositions and methods for treating and/or preventing cardiovascular disease
HK1180185B (en) Compositions for treating and/or preventing cardiovascular disease
HK1180185A (en) Compositions for treating and/or preventing cardiovascular disease
NZ763702B2 (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant